WHAT IS THE SCOPE AND QUALITY OF ECONOMIC EVIDENCE AVAILABLE FOR ATOPIC ECZEMA? A SYSTEMATIC REVIEW
Author(s)
Sach TH1, McManus E1, Levell N2, McOwan F3, Parris J3, Roberts A3, Thomas K3
1University of East Anglia, Norwich, UK, 2Norfolk and Norwich University Hospital, Norwich, UK, 3University of Nottingham, Nottingham, UK
OBJECTIVES: Atopic eczema is a chronic inflammatory skin disease, resulting in itchy, dry skin. Whilst the clinical effectiveness evidence for eczema is collated in the Global Resource of Eczema Trials (GREAT) database there is currently no such resource for economic evidence. Therefore, we undertook a systematic review with the aim of identifying the scope and quality of economic research for atopic eczema. METHODS: A systematic literature search was conducted on 22nd May 2017. Studies eligible for inclusion were primary empirical studies either reporting the results of a cost of illness study or evaluating the cost, utility or full economic evaluation of preventions or interventions for eczema. Two reviewers independently assessed studies for eligibility and performed data abstraction collecting details of the study characteristics, costing and outcome methods, and quality assessment. Methodological quality was assessed using the CHEERS checklist. Further details can be found on PROSPERO (CRD42015024633). RESULTS: CONCLUSIONS: The current level of economic evidence within eczema is much lower than that available for clinical outcomes. The limited range of interventions evaluated and the heterogeneity of methods used in the existing evidence suggest further economic research is needed to support commissioners making health funding decisions.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PRM56
Topic
Economic Evaluation, Methodological & Statistical Research, Study Approaches
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Modeling and simulation
Disease
Sensory System Disorders